333 related articles for article (PubMed ID: 26138461)
21. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
Laleman W; Van Landeghem L; Van der Elst I; Zeegers M; Fevery J; Nevens F
Gastroenterology; 2007 Feb; 132(2):709-19. PubMed ID: 17258737
[TBL] [Abstract][Full Text] [Related]
22. Mixed endothelin receptor antagonist, SB209670, decreases portal pressure in biliary cirrhotic rats in vivo by reducing portal venous system resistance.
Kojima H; Yamao J; Tsujimoto T; Uemura M; Takaya A; Fukui H
J Hepatol; 2000 Jan; 32(1):43-50. PubMed ID: 10673066
[TBL] [Abstract][Full Text] [Related]
23. Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling.
Reiberger T; Payer BA; Schwabl P; Hayden H; Horvatits T; Jäger B; Hummel T; Mitterhauser M; Trauner M; Fuhrmann V; Angermayr B; Peck-Radosavljevic M;
Liver Int; 2013 Apr; 33(4):561-8. PubMed ID: 23331709
[TBL] [Abstract][Full Text] [Related]
24. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase.
Trebicka J; Hennenberg M; Laleman W; Shelest N; Biecker E; Schepke M; Nevens F; Sauerbruch T; Heller J
Hepatology; 2007 Jul; 46(1):242-53. PubMed ID: 17596891
[TBL] [Abstract][Full Text] [Related]
25. KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins.
Marrone G; Maeso-Díaz R; García-Cardena G; Abraldes JG; García-Pagán JC; Bosch J; Gracia-Sancho J
Gut; 2015 Sep; 64(9):1434-43. PubMed ID: 25500203
[TBL] [Abstract][Full Text] [Related]
26. Effects of raloxifene on portal hypertension and hepatic encephalopathy in cirrhotic rats.
Chang CC; Lee WS; Chuang CL; Hsin IF; Hsu SJ; Chang T; Huang HC; Lee FY; Lee SD
Eur J Pharmacol; 2017 May; 802():36-43. PubMed ID: 28238769
[TBL] [Abstract][Full Text] [Related]
27. Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease.
Boyer-Diaz Z; Aristu-Zabalza P; Andrés-Rozas M; Robert C; Ortega-Ribera M; Fernández-Iglesias A; Broqua P; Junien JL; Wettstein G; Bosch J; Gracia-Sancho J
J Hepatol; 2021 May; 74(5):1188-1199. PubMed ID: 33278455
[TBL] [Abstract][Full Text] [Related]
28. Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.
Klein S; Rick J; Lehmann J; Schierwagen R; Schierwagen IG; Verbeke L; Hittatiya K; Uschner FE; Manekeller S; Strassburg CP; Wagner KU; Sayeski PP; Wolf D; Laleman W; Sauerbruch T; Trebicka J
Gut; 2017 Jan; 66(1):145-155. PubMed ID: 26385087
[TBL] [Abstract][Full Text] [Related]
29. Treatment of bile duct-ligated rats with the nitric oxide synthase transcription enhancer AVE 9488 ameliorates portal hypertension.
Biecker E; Trebicka J; Kang A; Hennenberg M; Sauerbruch T; Heller J
Liver Int; 2008 Mar; 28(3):331-8. PubMed ID: 18290775
[TBL] [Abstract][Full Text] [Related]
30. The beneficial effects of curcumin in cirrhotic rats with portal hypertension.
Hsu SJ; Lee JY; Lin TY; Hsieh YH; Huang HC; Lee FY; Lin HC; Hou MC; Lee SD
Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 29162665
[TBL] [Abstract][Full Text] [Related]
31. Antagonism of sphingosine 1-phosphate receptor 2 causes a selective reduction of portal vein pressure in bile duct-ligated rodents.
Kageyama Y; Ikeda H; Watanabe N; Nagamine M; Kusumoto Y; Yashiro M; Satoh Y; Shimosawa T; Shinozaki K; Tomiya T; Inoue Y; Nishikawa T; Ohtomo N; Tanoue Y; Yokota H; Koyama T; Ishimaru K; Okamoto Y; Takuwa Y; Koike K; Yatomi Y
Hepatology; 2012 Oct; 56(4):1427-38. PubMed ID: 22505286
[TBL] [Abstract][Full Text] [Related]
32. Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension.
Laviña B; Gracia-Sancho J; Rodríguez-Vilarrupla A; Chu Y; Heistad DD; Bosch J; García-Pagán JC
Gut; 2009 Jan; 58(1):118-25. PubMed ID: 18829979
[TBL] [Abstract][Full Text] [Related]
33. The Beneficial Effects of P2X7 Antagonism in Rats with Bile Duct Ligation-induced Cirrhosis.
Tung HC; Lee FY; Wang SS; Tsai MH; Lee JY; Huo TI; Huang HC; Chuang CL; Lin HC; Lee SD
PLoS One; 2015; 10(5):e0124654. PubMed ID: 25933224
[TBL] [Abstract][Full Text] [Related]
34. Role of beta3-adrenoceptors for intrahepatic resistance and portal hypertension in liver cirrhosis.
Trebicka J; Hennenberg M; Schulze Pröbsting A; Laleman W; Klein S; Granzow M; Nevens F; Zaagsma J; Heller J; Sauerbruch T
Hepatology; 2009 Dec; 50(6):1924-35. PubMed ID: 19842096
[TBL] [Abstract][Full Text] [Related]
35. HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects.
Klein S; Van Beuge MM; Granzow M; Beljaars L; Schierwagen R; Kilic S; Heidari I; Huss S; Sauerbruch T; Poelstra K; Trebicka J
J Hepatol; 2012 Dec; 57(6):1220-7. PubMed ID: 22878469
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of soluble epoxide hydrolase lowers portal hypertension in cirrhotic rats by ameliorating endothelial dysfunction and liver fibrosis.
Deng W; Zhu Y; Lin J; Zheng L; Zhang C; Luo M
Prostaglandins Other Lipid Mediat; 2017 Jul; 131():67-74. PubMed ID: 28822809
[TBL] [Abstract][Full Text] [Related]
37. Effect of sirolimus on liver cirrhosis and hepatic encephalopathy of common bile duct-ligated rats.
Wu KC; Huang HC; Chang T; Lee WS; Chuang CL; Hsin IF; Hsu SJ; Lee FY; Chang CC; Lee SD
Eur J Pharmacol; 2018 Apr; 824():133-139. PubMed ID: 29444470
[TBL] [Abstract][Full Text] [Related]
38. Vasopressin response and shunting modulation in cirrhotic rats by chronic nitric oxide inhibition.
Huang HC; Wang SS; Lee FY; Chang CC; Chang FY; Lin HC; Hou MC; Lee SD
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e265-9. PubMed ID: 17764528
[TBL] [Abstract][Full Text] [Related]
39. Neutral endopeptidase (EC 3.4.24.11) in cirrhotic liver: a new target to treat portal hypertension?
Sansoè G; Aragno M; Mastrocola R; Restivo F; Mengozzi G; Smedile A; Rosina F; Danni O; Parola M; Rizzetto M
J Hepatol; 2005 Nov; 43(5):791-8. PubMed ID: 16085334
[TBL] [Abstract][Full Text] [Related]
40. Effects of fasudil on the portal and systemic hemodynamics of patients with cirrhosis.
Fukuda T; Narahara Y; Kanazawa H; Matsushita Y; Kidokoro H; Itokawa N; Kondo C; Atsukawa M; Nakatsuka K; Sakamoto C
J Gastroenterol Hepatol; 2014 Feb; 29(2):325-9. PubMed ID: 24033356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
